Research interests
Her group was the first to define cardiac Bridging Integrator 1 (cBIN1) as a key regulator of myocardial remodeling[8]
Andriana P. Nikolova
Assistant Professor in Cardiology at Cedars-Sinai Medical Center
Current relationship
Assistant Professor in Cardiology at Cedars-Sinai Medical Center
Current relationship
Andriana Nikolova is a Cedars-Sinai cardiology faculty member whose work connects heart failure, cardiac transplantation, translational diagnostics, and emerging cardio-oncology. She describes herself as a trained physician-scientist in heart failure and cardiac transplantation and obtained a PhD in Biomedical sciences during cardiology training. Her research focuses on novel diagnostics for patients with heart failure and heart transplant recipients. Her group defined cardiac Bridging Integrator 1 (cBIN1) as a regulator of myocardial remodeling, and she led translational pilot studies applying the biomarker in HFpEF and cardiac allograft rejection. She has broadened her clinical and research interests to cardio-oncology and contributes to establishing a dedicated academic cardio-oncology program at Cedars-Sinai. In 2018, she was identified as a fourth-year cardiology fellow there.
Describes herself as a trained physician-scientist in heart failure and cardiac transplantation
Each topic is linked to its supporting source in Sources.
Training includes Obtained a PhD in Biomedical sciences during cardiology training, In 2018, an American College of Cardiology article identified her as a fourth-year general cardiology Fellow in Training (FIT) at Cedars-Sinai Medical Center in Los Angeles, California, Cardiovascular Disease Fellowship, and Internal Medicine Residency.
Explore education and trainingAs of 2026
As of 2017
Her group was the first to define cardiac Bridging Integrator 1 (cBIN1) as a key regulator of myocardial remodeling[8]
Researches novel diagnostics for patients with heart failure and heart transplant recipients[8]
Research interests include cardio-oncology[12]
Spearheaded translational pilot studies applying cBIN1 as a biomarker in cohorts of patients with HFpEF and cardiac allograft rejection[8]